Immunocore Holdings Ltd (IMCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) has a cash flow conversion efficiency ratio of -0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.46 Million) by net assets ($396.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Immunocore Holdings Ltd to measure how many days the company can operate on defensive assets alone.
Immunocore Holdings Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Immunocore Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immunocore Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunocore Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Opera Limited
F:2V8
|
0.043x |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
N/A |
|
Fujian Expressway Development Co Ltd
SHG:600033
|
0.045x |
|
Jiangsu Zhongchao Cable Co Ltd
SHE:002471
|
-0.010x |
|
Orizon Valorização de Resíduos S.A
SA:ORVR3
|
0.002x |
|
Orange Belgium SA
BR:OBEL
|
0.124x |
|
Eramet SA
PA:ERA
|
-0.064x |
|
Cogeco Communications Inc
TO:CCA
|
0.046x |
Annual Cash Flow Conversion Efficiency for Immunocore Holdings Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of Immunocore Holdings Ltd from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Immunocore Holdings Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $360.72 Million | $26.06 Million | 0.072x | +806.40% |
| 2023-12-31 | $368.84 Million | $2.94 Million | 0.008x | +105.49% |
| 2022-12-31 | $338.90 Million | $-49.21 Million | -0.145x | +76.51% |
| 2021-12-31 | $231.53 Million | $-143.11 Million | -0.618x | +43.52% |
| 2020-12-31 | $55.35 Million | $-60.57 Million | -1.094x | +78.87% |
| 2019-12-31 | $19.57 Million | $-101.38 Million | -5.181x | -1663.12% |
| 2018-12-31 | $56.58 Million | $-16.63 Million | -0.294x | -- |
About Immunocore Holdings Ltd
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more